Immunocore Holdings plc (IMCR) stock: key figures, P/E, revenue and dividend
Health Care · United Kingdom · ISIN US45258D1054
Immunocore Holdings plc financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 400.02 m USD |
| Gross profit | 394.93 m USD |
| Operating income | -45.35 m USD |
| EBIT | -23.41 m USD |
| Net income | -35.51 m USD |
| Diluted EPS – continuing operations | -0.71 USD |
Full history since 2013, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Immunocore Holdings plc
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
More stocks
- KSB SE & Co KGaA (KSB.DE)
- Live Oak Bancshares, Inc. (LOB)
- Jiangxi Guoke Defence Group Co. Ltd. A (688543.SS)
- Shanghai Hanbell Precise Machinery Co Ltd (002158.SZ)
- HORNBACH Holding AG & Co KgaA (HBH.DE)
- UroGen Pharma Ltd. (URGN)
- HYCROFT MINING HOLDING CORP (HYMC)
- Sichuan Injet Electric Co Ltd (300820.SZ)
- Hankook Tire Worldwide (000240.KS)
- New World Development Co Ltd (17.HK)
- Fujian Snowman Co Ltd (002639.SZ)
- HIAG Immobilien Holding AG (HIAG.SW)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.